These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 7564784)

  • 1. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
    Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
    Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group.
    Sata M; Ide T; Akiyoshi F; Fukuizumi K; Noguchi S; Shirachi M; Sasaki M; Uchimura Y; Suzuki H; Tanikawa K
    Kurume Med J; 1997; 44(3):171-7. PubMed ID: 9339647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon and hepatocellular carcinoma.
    Andreone P; Cursaro C; Gramenzi A; Trevisani F; Gasbarrini G; Bernardi M
    Lancet; 1996 Jan; 347(8995):195. PubMed ID: 8544566
    [No Abstract]   [Full Text] [Related]  

  • 6. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
    Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
    J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
    Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
    Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    Hung CH; Lee CM; Lu SN; Wang JH; Hu TH; Tung HD; Chen CH; Chen WJ; Changchien CS
    J Viral Hepat; 2006 Jun; 13(6):409-14. PubMed ID: 16842444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
    Valla DC; Chevallier M; Marcellin P; Payen JL; Trepo C; Fonck M; Bourliere M; Boucher E; Miguet JP; Parlier D; Lemonnier C; Opolon P
    Hepatology; 1999 Jun; 29(6):1870-5. PubMed ID: 10347132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.
    Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M
    Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.
    Kashiwagi K; Furusyo N; Kubo N; Nakashima H; Nomura H; Kashiwagi S; Hayashi J
    J Infect Chemother; 2003 Dec; 9(4):333-40. PubMed ID: 14691655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP).
    Fattovich G; Giustina G; Degos F; Diodati G; Tremolada F; Nevens F; Almasio P; Solinas A; Brouwer JT; Thomas H; Realdi G; Corrocher R; Schalm SW
    J Hepatol; 1997 Jul; 27(1):201-5. PubMed ID: 9252096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of cryoglobulinemia in chronic hepatitis C virus infection and response to treatment with interferon-alpha.
    Akriviadis EA; Xanthakis I; Navrozidou C; Papadopoulos A
    J Clin Gastroenterol; 1997 Dec; 25(4):612-8. PubMed ID: 9451674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.
    Nishiguchi S; Shiomi S; Nakatani S; Takeda T; Fukuda K; Tamori A; Habu D; Tanaka T
    Lancet; 2001 Jan; 357(9251):196-7. PubMed ID: 11213099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.